Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Chloe Gross"'
Autor:
Phyllis Bijole, Elana Rosenthal, Miriam Jones, Randy Kier, Julia D Mount, Laura Nussdorf, Poonam Mathur, Rachel Silk, Kristi Hill, Sarah Kattakuzhy, Dana McCullough, Shyam Kottilil, David Sternberg, Henry Masur, Chloe Gross
Publikováno v:
J Addict Med
OBJECTIVE The ANCHOR program offered buprenorphine treatment to people who inject drugs engaged in hepatitis C (HCV) treatment at a Washington, DC harm reduction organization. This analysis describes the program model and outcomes of the opioid care
Publikováno v:
The Journal for Nurse Practitioners. 16:267-270
Liver fibrosis evaluation is one of the most important assessments in patients with chronic hepatitis C. In an inner-city infectious disease clinic, more than 30% of patients with hepatitis C did not have complete evaluation for liver fibrosis, poten
Autor:
Elana Rosenthal, Poonam Mathur, David Sternberg, Rachel Silk, Randy Kier, Kristi Hill, Laura Nussdorf, Kristen A Stafford, Junfeng Sun, Nadeera Sidique, Christopher Brokus, Phyllis Bijole, Henry Masur, Aaron D’Amore, Rahwa Eyasu, Sarah Kattakuzhy, Chloe Gross, Shyamasundaran Kottilil, Miriam Jones, Dana McCullough
Publikováno v:
Clinical Infectious Diseases. 71:1715-1722
Background People who inject drugs have a high prevalence of hepatitis C virus (HCV) and significant disease associated with drug use; however, HCV treatment often occurs in absence of interventions to address opioid use disorder and drug use–relat
Autor:
Sarah Kattakuzhy, Julia Sheehan, Elizabeth Akoth, Elana Rosenthal, Colleen Hadigan, Chloe Gross, Shyam Kottilil, Henry Masur, Rachel Silk, Cheryl Chairez, Chloe S. Chaudhury
Publikováno v:
The Journal of Infectious Diseases. 217:47-50
Hepatitis C clearance with directly acting antivirals (DAAs) may be associated with acute decreases in hemoglobin A1c (HbA1c). We prospectively evaluated 251 chronic hepatitis C virus (HCV)-infected subjects (31% human immunodeficiency virus [HIV] po
Publikováno v:
Journal of the Association of Nurses in AIDS Care. 28:680-684
Autor:
Mary Ann McLaughlin, Elana Rosenthal, Sarah Kattakuzhy, Rachel Silk, Julia B Balmaceda, Cheryl Chairez, Olivia Belliveau, Chloe S. Chaudhury, Colleen Hadigan, David E. Kleiner, Julia Aepfelbacher, Shyam Kottilil, Chloe Gross
Publikováno v:
Antivir Ther
Background While acute changes in hepatic fibrosis are recognized shortly after achieving sustained virological response (SVR) using direct-acting antiviral therapies, long-term outcomes for the growing population of successfully treated patients wit
Publikováno v:
Journal of the Association of Nurses in AIDS Care. 27:524-529
A critical step in the eradication of hepatitis C virus (HCV) infection is access to effective therapy. With the advent of interferon-free regimens, HCV providers and patients gained hope that the success seen in clinical trials could be translated t
Autor:
Anu Osinusi, Amy Nelson, Henry Masur, Rachel Silk, Michael A. Polis, Sreetha Sidharthan, Michael A. Proschan, Chloe Gross, Lori A. Gordon, Shyam Kottilil, Tess Petersen, Monica Calderón, Anita Kohli, Kerry Townsend
Publikováno v:
Hepatology International
Background As treatment for chronic hepatitis C (HCV) virus has evolved to all-oral, interferon-free directly acting antiviral (DAA) therapy, the impact of these improvements on patient adherence has not been described. Methods Medication adherence w
Autor:
Sarah Kattakuzhy, Elana Rosenthal, Chloe Gross, Mary M. McLaughlin, Takara L. Stanley, Chloe S Chaudhury, Cheryl Chairez, Shyam Kottilil, Rachel Silk, Colleen Hadigan, Thomas Mee
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 69(4)
Background Hepatitis C virus (HCV) and hepatic dysfunction are associated with low total and free testosterone (TT and FT) and high sex hormone-binding globulin (SHBG). However, little is known about changes in testosterone following successful HCV t
Autor:
Anita Kohli, Rama Kapoor, Zayani Sims, Anu Osinusi, Rachel Silk, Henry Masur, Colleen Kotb, Amy Nelson, Brian Lam, Kate Sugarman, Michael A. Polis, Gebeyehu Teferi, Sreetha Sidharthan, Phillip S. Pang, Vinod K. Rustgi, Shyam Kottilil, Chloe Gross
Publikováno v:
The Lancet Infectious Diseases. 15:1049-1054
Summary Background Worldwide, although predominantly in low-income countries in the Middle East and Africa, up to 13% of hepatitis C virus (HCV) infections are caused by HCV genotype 4. For patients with HCV genotype 1, the combination of ledipasvir